home All News open_in_new Full Article

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including...


today 2 h. ago attach_file Economics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Economics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 3525005116
Add Watch Country

arrow_drop_down